GSK is hosting the third annual RespiVerse Meeting in Bangkok, Thailand. The event brings together renowned international ...
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...
The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...
GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...
GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...
GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...
Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...